Brief: CSL To Cease New Patient Initiation For Tavneos In EU And Eea Markets
29/06/2026 02:27
BRIEF-CSL To Cease New Patient Initiation For Tavneos In EU And Eea Markets June 29 (Reuters) - CSL Ltd CSL.AX:
TO CEASE NEW PATIENT INITIATION FOR TAVNEOS IN EU AND EEA MARKETS
EMA CHMP RECOMMENDS REVOCATION OF EU MARKETING AUTHORISATION FOR TAVNEOS ON JUN 26
TO PROVIDE DETAILS ON TAVNEOS IP IMPAIRMENT IN 2026 FULL YEAR RESULTS
EXPECTS FY26 TAVNEOS SALES REVENUE OF ABOUT $145 MILLION
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSL
See all newsAustralia's CSL faces investor proceeding over disclosure obligations (updated)
Australia's CSL faces investor proceeding over disclosure obligations
Citi says CSL's CEO pick brings key strengths
Australia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director